American Healthcare REIT, Inc.
AHR
$53.52
+1.10%
American Healthcare REIT, Inc. is a self-managed healthcare real estate investment trust that owns a diversified portfolio of clinical healthcare properties spanning medical office buildings, skilled nursing facilities, senior housing, hospitals, and other healthcare-related facilities, organized across four reportable segments: Integrated Senior Health Campuses, Outpatient Medical, Triple-Net Leased Properties, and SHOP. The company is a relative newcomer to the public markets, having listed on the NYSE in February 2024, and it differentiates itself through a heavy concentration in integrated senior health campuses — a vertically integrated model combining real estate with on-site care operations that generates the majority of its revenue and offers operational upside beyond a pure rent-collection REIT. The investor narrative is dominated by the company's rapid fundamental transformation: revenue has compounded sharply (Q2 2026 revenue of $674.25 million, up 24.3% year-over-year), NOI growth has been robust, and the company has swung from persistent quarterly losses in 2024 to consistent profitability through 2025 and 2026, driving a 21.9% one-year total return. Debate now centers on whether the senior housing operating portfolio (SHOP) can sustain its margin expansion as occupancy and rate growth mature, whether the aggressive acquisition and equity-issuance strategy is accretive to per-share cash flow, and how a still-thin 3.1% net margin and elevated payout ratio will evolve as the REIT scales.…
AHR
American Healthcare REIT, Inc.
$53.52
Related headlines
Investment Opinion: Should I buy AHR Today?
Rating: Hold with a constructive bias. The core thesis is that AHR is a genuinely growing healthcare REIT — 24.3% revenue growth, 16.4% NOI growth, and a unanimous strong-buy consensus with a $63.69 average target (20% upside) — but the current 112x trailing P/E and 234% payout ratio mean the stock already discounts much of that success. The analyst consensus and average target anchor a favorable view, but the valuation and balance-sheet metrics argue for patience rather than aggressive accumulation at $53.
Supporting evidence is mixed but leans positive on operations: revenue grew 24.3% YoY to $674.25 million, net income turned positive at $30.6 million (4.5% margin), EBITDA rose to $121.7 million from $84.8 million a year earlier, and free cash flow TTM is $261.8 million. The 2.1% dividend yield and 0.80 beta make it a reasonable defensive income holding. However, the 53.6x forward P/E, 26.1x EV/EBITDA, and 0.37 current ratio are well above what a typical healthcare REIT commands, so the operational strength is already substantially priced in.
The biggest risks that could invalidate the thesis are a SHOP margin stall, a dividend cut forced by the 234% payout ratio, and equity dilution from acquisition funding. This Hold would upgrade to Buy if the stock pulls back toward the $46-$48 range (roughly 15-20x forward EBITDA on a more normalized basis) or if forward P/E compresses below 40x on sustained margin expansion. It would downgrade to Sell if revenue growth decelerates below 10% or if the payout ratio is not brought under control within four quarters. Verdict: fairly valued to modestly overvalued relative to history and peers, with the operational story strong enough to justify holding but not chasing.
Sign up to view all
AHR 12-Month Price Forecast
The forward view is balanced: operational momentum is real and analyst sentiment is uniformly positive, but the valuation already embeds several years of successful execution. The base case (50% probability) sees the stock reaching the $55-$64 range as growth moderates but profitability holds, while the bull and bear cases are symmetric at 25% each. I would upgrade to bullish if Q3 2026 shows SHOP margins expanding alongside revenue growth above 20% and the payout ratio trending below 200%, or if the stock pulls back to the $46-$48 range. I would downgrade to bearish if revenue growth falls below 10% or if a dividend cut or large dilutive equity raise is announced.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on American Healthcare REIT, Inc.'s 12-month outlook, with a consensus price target around $63.69 and implied upside of +19.0% versus the current price.
Average Target
$63.69
0 analysts
Implied Upside
+19.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$55 - $74
Analyst target range
Bulls vs Bears: AHR Investment Factors
The bull case currently has stronger evidence: 24.3% revenue growth, four consecutive profitable quarters, 16.4% NOI growth, and a unanimous strong-buy consensus with a $63.69 average target all point to a company executing on its post-IPO transformation. However, the bear case is not weak — a 112x trailing P/E, 234% payout ratio, and 0.37 current ratio mean the stock is priced for perfection and financed with leverage. The single most important tension is whether SHOP margin expansion can continue as occupancy and rate growth mature; if margins stall, the 53.6x forward earnings multiple and 26.1x EV/EBITDA have substantial room to compress. Near-term momentum (-7.7% over three months, 10.5 points of relative underperformance) suggests the market is already beginning to test that thesis.
Bullish
- Revenue compounding at 24.3% YoY: Q2 2026 revenue reached $674.25 million, up 24.3% from $542.5 million in Q2 2025, extending a streak of double-digit growth across every quarter since the 2024 IPO. This trajectory is driven by both SHOP occupancy/rate gains and an aggressive acquisition program, and it is the single strongest evidence that the platform is scaling.
- Swing to consistent profitability: AHR posted net income of $30.6 million in Q2 2026 (4.5% net margin) versus $9.9 million in Q2 2025 and losses in 2024, with EPS of $0.16 versus $0.06 a year ago. The last four quarters have all been profitable, demonstrating that operating leverage is now flowing through to the bottom line.
- Analyst consensus strong buy, 20% upside: All 16 covering analysts rate the stock a strong buy (mean recommendation 1.375), with an average target of $63.69 versus the $53.02 current price — roughly 20% implied upside. Even the lowest target of $55 sits 3.7% above the current price, indicating no analyst sees downside from here.
- NOI growth and institutional validation: The company reported 16.4% NOI growth, and recent news highlights new institutional fund stakes in the name. For a REIT that only listed in February 2024, growing institutional ownership alongside 16%+ NOI growth supports the re-rating case.
Bearish
- Extreme valuation on earnings: The trailing P/E is 112x and forward P/E is 53.6x, with EV/EBITDA at 26.1x and P/CF at 26.5x — multiples that leave no room for execution error. A 3.1% net margin and 7.5% operating margin mean the earnings base is thin relative to the $7.8 billion market cap.
- Payout ratio of 234% is unsustainable: The dividend yield of 2.1% is being funded at a payout ratio of 234% of earnings, meaning the distribution is not covered by net income and depends on cash flow and capital markets access. If equity issuance becomes more expensive, the dividend and acquisition strategy could come under pressure.
- Weak liquidity and balance sheet: The current ratio of 0.37 indicates current liabilities far exceed current assets, and debt-to-equity of 0.51 adds leverage on top of a capital-intensive acquisition program. Interest expense of $18.6 million per quarter consumes a meaningful share of the $45.6 million in quarterly operating income.
- Momentum has broken down: Despite a 21.9% one-year return, the stock is down 7.7% over three months and has underperformed the S&P 500 by 10.5 percentage points in that window, falling from a 52-week high of $58.70 to $53.02. The 52-week low of $43.33 is 18% below the current price, showing how quickly sentiment can reverse.
AHR Technical Analysis
Beta
0.80
0.80x market volatility
Max Drawdown
-14.5%
Largest decline past year
52-Week Range
$45-$59
Price range past year
Annual Return
+18.1%
Cumulative gain past year
| Period | AHR Return | S&P 500 |
|---|---|---|
| 1m | +4.4% | -0.9% |
| 3m | -3.7% | +1.2% |
| 6m | +6.7% | +4.9% |
| 1y | +18.1% | +11.2% |
| ytd | +13.3% | +10.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AHR Fundamental Analysis
Quarterly Revenue
$674250000.0B
2026-06
Revenue YoY Growth
+24.3%
YoY Comparison
Gross Margin
-1.0%
Latest Quarter
Free Cash Flow
$261842000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AHR Overvalued?
PE
112.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 32x~243x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
26.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on a thin earnings base and stretched liquidity. Net margin is just 3.1% and operating margin 7.5%, so a modest cost increase in the SHOP segment — where AHR directly operates senior housing — could erase a large share of the $30.6 million quarterly net income. The current ratio of 0.37 means current liabilities are nearly three times current assets, and debt-to-equity of 0.51 plus $18.6 million in quarterly interest expense leaves limited cushion if refinancing costs rise. The 234% payout ratio means the 2.1% dividend is not covered by earnings and depends on free cash flow of $261.8 million TTM and continued access to equity capital, which also funds the acquisition program that drives revenue growth.
Market and competitive risks are dominated by valuation compression. At 112x trailing and 53.6x forward earnings, AHR trades at a steep premium to typical healthcare REIT multiples, and EV/EBITDA of 26.1x assumes sustained NOI growth that peers do not require. Beta of 0.80 offers some defensiveness, but the stock's 10.5-point three-month underperformance versus the S&P 500 shows that sector rotation out of rate-sensitive REITs can hit even low-beta names. The 10.06 short ratio indicates active bearish positioning that could accelerate a downdraft on any SHOP occupancy miss, and competition for senior housing assets from larger, lower-cost REITs could pressure acquisition cap rates and per-share accretion.
In a worst-case scenario, SHOP occupancy and rate growth decelerate simultaneously, margin expansion reverses, and the company must issue equity at a depressed price to fund acquisitions and the dividend. That combination would compress the forward multiple toward peer REIT levels and could take the stock to its 52-week low of $43.33 — an 18.3% decline from $53.02 — or below if the dividend is cut. The maximum drawdown over the observed period was already -14.47%, and the analyst low target of $55 offers little downside protection because it sits above the current price. A realistic adverse case is a 20-30% drawdown to the $37-$43 range if both earnings and multiple contract.
FAQ
The most severe risk is valuation compression: at 53.6x forward earnings and 26.1x EV/EBITDA, any slowdown in SHOP margin expansion could trigger a sharp re-rating toward peer REIT multiples. Second is dividend sustainability, with a 234% payout ratio meaning the 2.1% yield is not covered by net income and could be cut. Third is balance-sheet liquidity, with a 0.37 current ratio and $18.6 million in quarterly interest expense leaving little cushion. Fourth is dilution risk from equity issuance to fund acquisitions, which could pressure per-share cash flow. Ranked by severity: valuation, dividend coverage, liquidity, and dilution.
The 12-month forecast has three scenarios: a 25% probability bull case targeting $63.69-$74.00 if SHOP margins and NOI growth persist, a 50% probability base case targeting $55.00-$63.69 as growth moderates to the high-teens, and a 25% probability bear case targeting $43.33-$55.00 if margin expansion stalls or the dividend is cut. The base case is most likely, anchored by the $63.69 analyst average target and the assumption that revenue growth decelerates from 24.3% but profitability holds near 3-4% net margin. The key assumption behind the base case is that SHOP occupancy and rate growth remain positive enough to offset rising interest expense.
AHR screens as overvalued on most traditional metrics: 112x trailing P/E, 53.6x forward P/E, 26.1x EV/EBITDA, and 26.5x price-to-cash-flow, all well above typical healthcare REIT multiples in the mid-teens to low-20s on EBITDA. The 3.46x price-to-sales ratio is more moderate but still reflects a premium for the SHOP operating model. The market is paying up for 24.3% revenue growth and the expectation that margins will scale as the portfolio matures. If that expectation is met, the forward multiple could compress through earnings growth rather than price declines; if it is not, the premium is vulnerable. On balance, the stock is fairly valued to modestly overvalued relative to its own history and peers.
From a risk/reward perspective, AHR offers roughly 20% upside to the $63.69 analyst average target against 18% downside to the $43.33 52-week low, a roughly balanced setup. The operational story is strong — 24.3% revenue growth, four consecutive profitable quarters, and 16.4% NOI growth — and all 16 analysts rate it a strong buy. However, the 112x trailing P/E and 234% payout ratio mean the stock is priced for continued execution, and the 0.37 current ratio adds balance-sheet risk. It is a good buy for growth-oriented investors with a multi-year horizon who can tolerate volatility, particularly on a pullback toward $46-$48; it is less suitable for income-focused investors given the uncovered dividend.
AHR is better suited to a medium-to-long-term horizon of at least two to three years. It is a growth-stage REIT that only listed in February 2024, with a 0.80 beta and a 2.1% dividend yield that is currently uncovered, so it does not offer the stable income profile of a mature REIT. Earnings visibility is improving but still limited by the SHOP operating model and acquisition-driven growth, and the 10.06 short ratio implies elevated volatility around earnings. Short-term traders could play the range between $43.33 and $58.70, but the fundamental thesis — margin expansion and per-share accretion — needs multiple quarters to play out. A minimum holding period of 24 months is suggested.